Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.71 |
| ▸ | GABRD | O14764 | 1/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.71 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.71 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.71 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.71 |
| ▸ | GABRE | P78334 | 1/20 | 0.71 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.71 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.71 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.71 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.71 |
| ▸ | CCKBR | P32239 | 16/20 | 0.56 |
| ▸ | CCKAR | P32238 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9379750 | 0.85 | GABRP (0.69) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1835654 | 0.84 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2929181 | 0.84 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2923672 | 0.84 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3287928 | 0.83 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7304003 | 0.81 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3487036 | 0.81 | GABRP (0.70) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3486697 | 0.80 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9432235 | 0.78 | GABRP (0.82) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9432239 | 0.78 | GABRP (0.82) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-7053084-B1 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | GABRP 14/4885GABRD 12/4885GABRA1 8/4885 |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | BACE1, APP, APH1B | GABRP 47/4885GABRD 65/4885GABRA1 135/4885 |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | GABRP 8/4885GABRD 16/4885GABRA1 4/4885 |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, GABRE | GABRP 6/4885GABRD 15/4885GABRA1 8/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | GABRP 6/4885GABRD 15/4885GABRA1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.